ContraFect Corp CFRXQ

Healthcare Biotechnology

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase, is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its exebacase is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.

GREY:CFRXQ - Post by User

ContraFect Corp > it's a buy today for me

<< Previous

Bullboard Posts

Next >>

Comment by MarineJumperon Jan 24, 2020 8:45pm

127 Views

Post# 30597402

RE:it's a buy today for me

Backed by Pfiizer and Federated to 30% ownership. Locked and loaded , may add more post agm end of month. Look at CVM (Cel-Sci) , nearing final read out. Do your own DD. GL

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide